Everest Medicines Announces NEFECON® Inclusion in China’s Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)" (hereinafter referred to as the "Guideline (Draft)")...
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND)...
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
ISLAMABAD, May 23, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). The collaboration will see the deployment of Chiron and Ava-AutoNarrator™—two proprietary, AGI-powered agents—across IDC's core diagnostic workflows. ...
CARsgen’s Satri-cel Abstract Available on ASCO Website
SHANGHAI, May 23, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for...
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1),...
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting
TAIPEI, May 23, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which is held in Chicago, USA, from May 30 to Jun 04, 2025. Abstract: 2574 Title: Preclinical development...
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /PRNewswire/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos® Inc.,...
Pictor Establishes U.S. Headquarters and Scales Operations, Revolutionizing Proteomics Testing Amid Regulatory Shift
CARLSBAD, Calif., May 22, 2025 /PRNewswire/ -- Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to advancing cutting-edge solutions for laboratories worldwide. This transformation solidifies Pictor...
NYSE Content Advisory: Pre-Market update + Hinge Health, MNTN go public
NEW YORK, May 22, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on May 22nd Hinge Health (NYSE: HNGE),...
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on cell therapy drugs for ophthalmic diseases. Porton Advanced will provide comprehensive CDMO services to support iPSC-derived retinal pigment epithelium cell (RPEC)...
